AstraZeneca Plc, through its wholly-owned rare disease business unit Alexion, is to buy a portfolio of preclinical gene therapy programmes from Pfizer Inc. The deal will bring together Alexion’s expertise in rare disease medicines with AstraZeneca’s growing presence in the field of cell and gene therapy.
